While I'd never suggest that you can simply buy innovation, access to greater resources can be hugely impactful in the medical field. Life Tech and Illumina are already pushing the cost of sequencing a full genome down into the three-digit cost range, and when (not if) those costs approach comparable levels to blood work, you can expect to see doctors start making just as much use of genome screening as they do blood work, if not more. The market opportunity is effectively every human being alive with access to medical care, and the company that reaches a wide swath of doc offices first will have a very strong case for market dominance. Will Illumina race ahead of Life Tech when costs drop again? That remains to be seen.